Markers for individualised therapy in endometrial carcinoma

The Lancet Oncology

Volumn 13, Issue 8, 2012, Pages

  Salvesen, Helga B ^a,b   Haldorsen, Ingfrid S ^a,b   Trovik, Jone ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ARZOXIFENE; BETA CATENIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; ENDOXIFEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FLUORODEOXYGLUCOSE F 18; FULVESTRANT; GROWTH DIFFERENTIATION FACTOR 15; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; MEDROXYPROGESTERONE; MEGESTROL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN KINASE B; PROTEIN P16; PROTEIN P53; RIDAFOROLIMUS; STATHMIN; TEMSIROLIMUS; TRASTUZUMAB; TUMOR MARKER; UNINDEXED DRUG; VASCULOTROPIN;

ANEUPLOIDY; CANCER CLASSIFICATION; CANCER CONTROL; CANCER DIAGNOSIS; CANCER INVASION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CDKN2A GENE; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; DNA METHYLATION; DRUG TARGETING; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ER GENE; ERBB2 GENE; EXTERNAL BEAM RADIOTHERAPY; GENE AMPLIFICATION; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; HIGH RISK PATIENT; HISTOLOGY; HUMAN; HYSTERECTOMY; KRAS GENE; LYMPH NODE METASTASIS; LYMPHADENECTOMY; METASTASIS; MLH1 GENE; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; MSI GENE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; PERSONALIZED MEDICINE; PI3KCA GENE; POPULATION RESEARCH; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PR GENE; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PTEN GENE; RETROSPECTIVE STUDY; REVIEW; RISK BENEFIT ANALYSIS; SALPINGOOOPHORECTOMY; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TP53 GENE; TUMOR LOCALIZATION; TUMOR SUPPRESSOR GENE; UTERINE CERVIX TUMOR;

CARCINOMA; CHEMOTHERAPY, ADJUVANT; DECISION SUPPORT TECHNIQUES; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYSTERECTOMY; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; RISK FACTORS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84864330983     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70213-9     Document Type: Review

References (75)

1. Jemal A, Siegel R, Xu J, Ward E Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I Endometrial cancer. Lancet 2005, 366:491-505.
3. Rose PG Endometrial carcinoma. N Engl J Med 1996, 335:640-649.
4. Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010, 375:816-823. the PORTEC Study Group.
5. Blake P, Swart AM, Orton J, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 2009, 373:137-146. the ASTEC/EN.5 Study Group.
6. Tangjitgamol S, See HT, Kavanagh J Adjuvant chemotherapy for endometrial cancer. Int J Gynecol Cancer 2011, 21:885-895.
7. Oza AM, Elit L, Tsao MS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol 2011, 29:3278-3285.
8. Dedes KJ, Wetterskog D, Ashworth A, Kaye SB, Reis-Filho JS Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol 2011, 8:261-271.
9. Salvesen HB, Carter SL, Mannelqvist M, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci USA 2009, 106:4834-4839.
10. Taube SE, Clark GM, Dancey JE, McShane LM, Sigman CC, Gutman SI A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. J Natl Cancer Inst 2009, 101:1453-1463.
11. Bokhman JV Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983, 15:10-17.
12. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95. Biomarkers Definitions Working Group.
13. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991, 40:55-65.
14. Creutzberg CL, van Putten WL, Wárlám-Rodenhuis CC, et al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol 2004, 22:1234-1241. the postoperative Radiation Therapy in Endometrial Carcinoma Trial.
15. Wang X, Zhang H, Di W, Li W Clinical factors affecting the diagnostic accuracy of assessing dilation and curettage vs frozen section specimens for histologic grade and depth of myometrial invasion in endometrial carcinoma. Am J Obstet Gynecol 2009, 201:194.e1. 194.10.
16. Mitchard J, Hirschowitz L Concordance of FIGO grade of endometrial adenocarcinomas in biopsy and hysterectomy specimens. Histopathology 2003, 42:372-378.
17. Sala E, Wakely S, Senior E, Lomas D MRI of malignant neoplasms of the uterine corpus and cervix. AJR Am J Roentgenol 2007, 188:1577-1587.
18. Kinkel K, Forstner R, Danza FM, et al. Staging of endometrial cancer with MRI: guidelines of the European Society of Urogenital Imaging. Eur Radiol 2009, 19:1565-1574. the European Society of Urogenital Imaging.
19. Basu S, Li G, Alavi A PET and PET-CT imaging of gynecological malignancies: present role and future promise. Expert Rev Anticancer Ther 2009, 9:75-96.
20. Haldorsen IS, Salvesen HB Staging of endometrial carcinomas with MRI using traditional and novel MRI techniques. Clin Radiol 2012, 67:2-12.
21. Savelli L, Ceccarini M, Ludovisi M, et al. Preoperative local staging of endometrial cancer: transvaginal sonography vs. magnetic resonance imaging. Ultrasound Obstet Gynecol 2008, 31:560-566.
22. Haldorsen IS, Husby JA, Werner HM, et al. Standard 1.5-T MRI of endometrial carcinomas: modest agreement between radiologists. Eur Radiol 2012, published online March 28. 10.1007/s00330-012-2400-y.
23. Alcázar JL, Jurado M Three-dimensional ultrasound for assessing women with gynecological cancer: a systematic review. Gynecol Oncol 2011, 120:340-346.
24. Lin G, Ho KC, Wang JJ, et al. Detection of lymph node metastasis in cervical and uterine cancers by diffusion-weighted magnetic resonance imaging at 3T. J Magn Reson Imaging 2008, 28:128-135.
25. Narayanan P, Iyngkaran T, Sohaib SA, Reznek RH, Rockall AG Magnetic resonance lymphography: a novel technique for lymph node assessment in gynecologic malignancies. Cancer Biomark 2009, 5:81-88.
26. Lewin SN, Herzog TJ, Barrena Medel NI, et al. Comparative performance of the 2009 international Federation of gynecology and obstetrics' staging system for uterine corpus cancer. Obstet Gynecol 2010, 116:1141-1149.
27. Werner HM, Trovik J, Marcickiewicz J, et al. Revision of FIGO surgical staging in 2009 for endometrial cancer validates to improve risk stratification. Gynecol Oncol 2012, 125:103-108. the MoMaTEC study group.
28. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987, 60(suppl):2035-2041.
29. Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008, 100:1707-1716.
30. Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet 2010, 375:1165-1172.
31. Creasman WT The current status of lymphadenectomy in the management of endometrial cancer. Womens Health (Lond Engl) 2011, 7:33-35.
32. Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009, 373:125-136. the ASTEC study group.
33. Chan JK, Sherman AE, Kapp DS, et al. Influence of gynecologic oncologists on the survival of patients with endometrial cancer. J Clin Oncol 2011, 29:832-838.
34. Sharma C, Deutsch I, Lewin SN, et al. Lymphadenectomy influences the utilization of adjuvant radiation treatment for endometrial cancer. Am J Obstet Gynecol 2011, 205:562-569. e1-9.
35. Trovik J, Mauland KK, Werner HM, Wik E, Helland H, Salvesen HB Improved survival related to changes in endometrial cancer treatment, a 30-year population based perspective. Gynecol Oncol 2012, 125:381-387.
36. Scholten AN, Smit VT, Beerman H, van Putten WL, Creutzberg CL Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma. Cancer 2004, 100:764-772.
37. Lax SF, Kurman RJ, Pizer ES, Wu L, Ronnett BM A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis. Am J Surg Pathol 2000, 24:1201-1208.
38. McCluggage WG, Hirschowitz L, Wilson GE, Oliva E, Soslow RA, Zaino RJ Significant variation in the assessment of cervical involvement in endometrial carcinoma: an interobserver variation study. Am J Surg Pathol 2011, 35:289-294.
39. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000, 88:814-824.
40. Lax SF Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 2004, 444:213-223.
41. Salvesen HB, MacDonald N, Ryan A, et al. Methylation of hMLH1 in a population-based series of endometrial carcinomas. Clin Cancer Res 2000, 6:3607-3613.
42. Basil JB, Goodfellow PJ, Rader JS, Mutch DG, Herzog TJ Clinical significance of microsatellite instability in endometrial carcinoma. Cancer 2000, 89:1758-1764.
43. Engelsen IB, Stefansson IM, Akslen LA, Salvesen HB GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival. Am J Obstet Gynecol 2008, 199:543-547.
44. Morrison C, Zanagnolo V, Ramirez N, et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol 2006, 24:2376-2385.
45. Oda K, Stokoe D, Taketani Y, McCormick F High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 2005, 65:10669-10673.
46. Risinger JI, Hayes K, Maxwell GL, et al. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res 1998, 4:3005-3010.
47. Trovik J, Wik E, Stefansson IM, et al. Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer. Clin Cancer Res 2011, 17:3368-3377. the MoMaTec Study Group.
48. Engelsen IB, Stefansson I, Akslen LA, Salvesen HB Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas. Am J Obstet Gynecol 2006, 195:979-986.
49. Salvesen HB, Das S, Akslen LA Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin Cancer Res 2000, 6:153-159.
50. Stefansson IM, Salvesen HB, Akslen LA Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol 2004, 22:1242-1252.
51. Schlosshauer PW, Ellenson LH, Soslow RA Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype. Mod Pathol 2002, 15:1032-1037.
52. Moreno-Bueno G, Hardisson D, Sarrió D, et al. Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. J Pathol 2003, 199:471-478.
53. Dutt A, Salvesen HB, Chen TH, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci USA 2008, 105:8713-8717.
54. Pradhan M, Abeler VM, Danielsen HE, et al. Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium. Ann Oncol 2012, 23:1178-1184.
55. Engelsen IB, Stefansson IM, Beroukhim R, et al. HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. Int J Oncol 2008, 32:307-316.
56. Mariani A, Sebo TJ, Katzmann JA, et al. Pretreatment assessment of prognostic indicators in endometrial cancer. Am J Obstet Gynecol 2000, 182:1535-1544.
57. Wik E, Trovik J, Iversen OE, et al. Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting. Am J Obstet Gynecol 2009, 201:603-607.
58. Creasman WT Prognostic significance of hormone receptors in endometrial cancer. Cancer 1993, 71(suppl):1467-1470.
59. Singh M, Zaino RJ, Filiaci VJ, Leslie KK Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2007, 106:325-333.
60. Kauppila AJ, Isotalo HE, Kivinen ST, Vihko RK Prediction of clinical outcome with estrogen and progestin receptor concentrations and their relationships to clinical and histopathological variables in endometrial cancer. Cancer Res 1986, 46:5380-5384.
61. Kokka F, Brockbank E, Oram D, Gallagher C, Bryant A Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database Syst Rev 2010, 12:CD007926.
62. Oreskovic S, Babic D, Kalafatic D, Barisic D, Beketic-Oreskovic L A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma. Gynecol Oncol 2004, 93:34-40.
63. Iversen OE Flow cytometric deoxyribonucleic acid index: a prognostic factor in endometrial carcinoma. Am J Obstet Gynecol 1986, 155:770-776.
64. Susini T, Amunni G, Molino C, et al. Ten-year results of a prospective study on the prognostic role of ploidy in endometrial carcinoma: dNA aneuploidy identifies high-risk cases among the so-called 'low-risk' patients with well and moderately differentiated tumors. Cancer 2007, 109:882-890.
65. Stefansson IM, Salvesen HB, Immervoll H, Akslen LA Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type. Histopathology 2004, 44:472-479.
66. Salvesen HB, Iversen OE, Akslen LA Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol 1999, 17:1382-1390.
67. Slomovitz BM, Broaddus RR, Burke TW, et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 2004, 22:3126-3132.
68. Silverman MB, Roche PC, Kho RM, Keeney GL, Li H, Podratz KC Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma. Gynecol Oncol 2000, 77:1-7.
69. Saal LH, Johansson P, Holm K, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 2007, 104:7564-7569.
70. Su D, Smith SM, Preti M, et al. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer 2009, 115:2453-2463.
71. Staff AC, Trovik J, Eriksson AG, et al. Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer. Clin Cancer Res 2011, 17:4825-4833.
72. Brooks AN, Kilgour E, Smith PD Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res 2012, 18:1855-1862.
73. Janku F, Wheler JJ, Westin SN, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012, 30:777-782.
74. Jiang W, Freidlin B, Simon R Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. J Natl Cancer Inst 2007, 99:1036-1043.
75. Halle MK, Werner HM, Krakstad C, et al. Stratification based on high tumour cell content in fresh frozen tissue promotes selection of aggressive endometrial carcinomas. Histopathology 2012, 60:516-519.